复发脑转移瘤的挽救性立体定向放疗:系统综述
汇总1年局部失败率为24%,放射性坏死约13%,挽救性SRS2后中位总生存为14个月。结论认为SRT2在选定患者中可提供有意义的局部控制和生存获益,毒性可接受。
要点
- 挽救性SRT2的1年局部失败率为24%,放射性坏死约13%。
- 挽救性SRS2后中位总生存为14个月。
- 放射性坏死多在治疗后4–8个月出现,与较大肿瘤体积和较高处方剂量相关。
核心结论
- 挽救性SRS2/SRT2在选定复发脑转移患者中可提供有意义的局部控制和生存获益,毒性谱可接受。
- 该策略可作为有效的非手术挽救选择,但仍需前瞻性研究明确最佳治疗参数和患者选择。
研究设计与样本
- 共纳入914例患者和2352个脑转移灶,其中389个病灶接受挽救性SRS2/SRT2治疗。
- 排除既往接受过全脑放疗的患者,采用随机效应模型汇总局部控制、总生存和放射性坏死数据。
主要发现
- 汇总1年局部失败率为24%。
- 放射性坏死发生率约为13%。
- 挽救性SRS2后中位总生存为14个月。
- 放射性坏死通常发生在治疗后4–8个月,并与较大肿瘤体积和较高处方剂量相关。
- 研究间存在中等异质性,关于多分次方案影响的结论需谨慎解读。
关键数值与推荐
- 汇总1年局部失败率为24%。
- 放射性坏死发生率约为13%。
- 挽救性SRS2后中位总生存为14个月。
- 放射性坏死通常发生于治疗后4–8个月。
临床怎么用
- 对既往未接受全脑放疗的野内复发脑转移患者,可考虑挽救性SRS2/SRT2作为非手术挽救选项。
- 治疗决策需权衡局部失败与放射性坏死风险,尤其对较大肿瘤体积和较高处方剂量者。
- 多分次方案的选择应谨慎,需结合个体情况并期待前瞻性研究进一步明确。
局限性
- 纳入研究均为回顾性研究。
- 研究间存在中等异质性。
- 关于多分次方案影响的结论需谨慎解读。
- 仍需前瞻性研究明确最佳治疗参数和患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiotherapy (SRT), including stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (hfSRT), plays a key role in the management of brain metastases (BM). As advances in systemic therapies prolong survival, local recurrence of BM has become more frequent, prompting interest in salvage reirradiation strategies. OBJECTIVE: This systematic review aimed to evaluate the efficacy and safety of a second course of stereotactic radiotherapy (SRT2) for in-field recurrent brain metastases. METHODS: Data on local control, overall survival, and radionecrosis were extracted and pooled using random-effects models. Eleven retrospective studies published between 2020 and 2025 were included, comprising 914 patients and 2,352 brain metastases, with 389 lesions treated with salvage SRS2/SRT2. Patients who had received prior whole-brain radiotherapy were excluded. RESULTS: The pooled 1-year local failure rate was 24%, and radionecrosis occurred in approximately 13% of cases. Median overall survival after salvage SRS2 was 14 months. Radionecrosis typically occurred within 4–8 months post-treatment and was associated with larger tumor volume and higher prescribed dose. Moderate heterogeneity was observed across studies, and conclusions regarding the impact of multifraction regimens should be interpreted cautiously. CONCLUSION: Salvage SRS2/SRT2 appears to provide meaningful local control and survival benefit in selected patients with recurrent brain metastases, with an acceptable toxicity profile. These findings support its role as an effective non-surgical salvage option, although prospective studies are needed to better define optimal treatment parameters and patient selection.
引用
- Laabid K, Abahssain H, Audouard RM, et al. Salvage stereotactic radiotherapy for locally recurrent brain metastases: a systematic review. Radiat Oncol. 2026. PMID: 41820993. doi:10.1186/s13014-026-02826-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。